Press release
United Therapeutics Corporation Announces Full Enrollment of the TETON 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis
Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression Top line
About this update from United Therapeutics Corporation
[{"type":"text","content":"\nOver 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression\n\n\nTop line data expected in the first half of 2026\n\n\n SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of Tyvaso® (treprostinil) inhalation solution (nebulized Tyvaso) for the treatment of idiopathic pulmonary fibrosis (IPF).\n\n\nThe TETON 1 study enrolled 598 patients and is part of the three-study global TETON clinical trial program evaluating the use of inhaled treprostinil in IPF and a similar condition, progressive pulmonary fibrosis (PPF). TETON 1 is evaluating the use of inhaled treprostinil in IPF in patients in the United States and Canada. TETON 2 is evaluating the use of inhaled treprostinil in IPF in patients outside the United States and Canada. TETON PPF is evaluating the use of inhaled treprostinil in PPF in patients globally. Patients in any of the TETON program studies may use nebulized Tyvaso alone as a monotherapy or in combination with one background therapy approved for the treatment of IPF or PPF. Enrollment in TETON 2 completed in July 2024 and top-line data for that study is expected in the second half of 2025. Enrollment in TETON PPF is ongoing.\n\n\n“Completing enrollment in this trial brings us one step closer to potentially delivering a transformative and much needed treatment option for this vulnerable group of patients living with IPF,” said Peter Smith, Pharm. D., Vice President, Product Development at United Therapeutics and the lead for the global TETON program. “Each of the participants in this study represents someone seeking better outcomes and improved quality of life. Their willingness to participate, along with the commitment of our investigators, moves us forward in our mission to deliver novel therapies that address significant challenges for patients and meaningfully impact the standard of care.”\n\n\nThe TETON program in IPF and PPF was prompted by data from the INCREASE study of nebulized Tyvaso for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), which demonstrated in a post-hoc analysis that treatment with nebulized Tyvaso resul...